658: Higano CS. New developments in the treatment of castration-resistant
prostate cancer. J Natl Compr Canc Netw. 2014 May;12(5 Suppl):773-6. PubMed PMID:
24853214.


659: Higano CS. Potential use of custirsen to treat prostate cancer. Onco Targets
Ther. 2013 Jun 25;6:785-97. doi: 10.2147/OTT.S33077. Print 2013. PubMed PMID:
23836992; PubMed Central PMCID: PMC3699352.


660: Higano CS, Crawford ED. New and emerging agents for the treatment of
castration-resistant prostate cancer. Urol Oncol. 2011 Nov-Dec;29(6 Suppl):S1-8. 
doi: 10.1016/j.urolonc.2011.08.013. Review. PubMed PMID: 22074657.


661: Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P,
Kantoff PW. Sipuleucel-T. Nat Rev Drug Discov. 2010 Jul;9(7):513-4. doi:
10.1038/nrd3220. PubMed PMID: 20592741.


662: Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost
N, Frohlich MW. Integrated data from 2 randomized, double-blind,
placebo-controlled, phase 3 trials of active cellular immunotherapy with
sipuleucel-T in advanced prostate cancer. Cancer. 2009 Aug 15;115(16):3670-9.
doi: 10.1002/cncr.24429. PubMed PMID: 19536890.


663: Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, Simons 
JW, Sacks N, Aimi J, Small EJ. Phase 1/2 dose-escalation study of a
GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic
hormone-refractory prostate cancer. Cancer. 2008 Sep 1;113(5):975-84. doi:
10.1002/cncr.23669. PubMed PMID: 18646045.


664: Higano CS, Vogelzang NJ, Sosman JA, Feng A, Caron D, Small EJ. Safety and
biological activity of repeated doses of recombinant human Flt3 ligand in
patients with bone scan-negative hormone-refractory prostate cancer. Clin Cancer 
Res. 2004 Feb 15;10(4):1219-25. PubMed PMID: 14977818.